MW Medtronic credits heart-surgery-device growth as profit tops analyst estimates
By Steve Gelsi
Medtronic's adjusted third-quarter profit tops analyst estimates
Medtronic PLC said its revenue grew nearly 3% on strength in its cutting-edge heart-surgery devices as the medical-technology company's adjusted profit topped analyst estimates.
Medtronic $(MDT)$ said its devices for a heart treatment called pulsed-field ablation helped drive growth as it reported adjusted third-quarter earnings of $1.39 a share, ahead of the FactSet consensus estimate of $1.36 a share.
Revenue rose 2.5% to $8.29 billion, slightly below the analyst expectation of $8.33 billion.
The company said its pulsed-field-ablation product revenue increased by more than 20%.
"We are starting to see the results from our long term investments in groundbreaking innovation, such as pulsed field ablation," Chief Executive Geoff Martha said in a prepared statement.
Medtronic still expects to report adjusted earnings of $5.44 a share to $5.50 a share for 2025, compared with the analyst estimate of $5.45 a share.
Medtronic's stock fell 2.4% in premarket trading on Tuesday.
The stock has risen 16.2% so far in 2025, while the S&P 500 SPX has risen 4%.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
February 18, 2025 07:19 ET (12:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。